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INTRODUCTION: Anal canal adenocarcinoma is an extremely rare malignancy with poorly deﬁned diag-
nostic and treatment criteria.
PRESENTATION OF CASE: A 42-year-old women was diagnosed with primary anal canal adenocarcinoma
11 months after undergoing anterior resection for primary sporadic rectal adeocarcinoma. Transanal
excision was performed and additional adjuvant chemotherapy was given. Immunohistology showed
positivity for cytokeratin (CK) 20 and CDX2, and negative CK7, which is compatible with colorectal sub-
type anal adenocarcinoma. At 6 months follow-up the patient has no evidence of recurrent or metastatic
disease.
DISCUSSION: Diagnosis of primary anal adenocarcinoma is typically delayed because of its rarity, and
vague clinical presentation. Exact histologic criteria remain poorly deﬁned but the use of immunohis-
tology has improved the overall diagnostic accuracy of anal adenocarcinoma and it also helps deﬁne
its correct origin. Reports on the management and outcomes of this cancer consist mainly of retrospec-
tive studies with no consistent treatment strategy and limited comparison data. Most authors currently
recommend neoadjuvant chemoradiotherapy and radical resection. Despite aggressive therapy, rates of
local failure and distant recurrence remain high.
CONCLUSION: Diagnosis of adenocarcinoma of the anal canal is difﬁcult but speciﬁc immunohistolgic
patterns help to correctly identify its correct origin and subtype. Deﬁning the correct subtype of anal
adenocarcinoma may impact treatment strategies of this rare cancer.
© 2014 The Authors. Published by Elsevier Ltd. on behalf of Surgical Associates Ltd. This is an open
he CCaccess article under t
. Introduction
Anal canal adenocarcinoma is a rare gastrointestinal tumor;
omprising 5–19% of all anal canal malignancies.1 Standard treat-
ent for adenocarcinoma of the anal canal has not been clearly
eﬁned, mainly because of the rarity of this malignancy. Treatment
odalities include combined chemoradiotherapy, local excision,
nd radical excision with abdominoperineal resection. Treatment
utcomes are scarce and limited to small retrospective studies and
ase reports,with noprospective and limited comparative data.We
resent a case of metachronous anal canal adenocarcinoma occur-
ing after anterior resection and adjuvant chemoradiotherapy for a
rimary rectal adenocarcinoma.∗ Corresponding author at: Division of Colon and Rectal Surgery, Department of
urgery, American British Medical Center, Sur 136 #116 1-A, Mexico City 01119,
exico. Tel.: +52 55 5272 3327.
E-mail address: gaert015@umn.edu (W.B. Gaertner).
ttp://dx.doi.org/10.1016/j.ijscr.2014.07.021
210-2612/© 2014 The Authors. Published by Elsevier Ltd. on behalf of Surgical Associate
http://creativecommons.org/licenses/by-nc-nd/3.0/).BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
2. Presentation of case
A 42 year old women with no signiﬁcant past medical history
presented with intermittent hematochezia of 1 month duration.
She denied abdominal pain, constipation, or family history of
colorectal cancer. Physical examination revealed mild hemor-
rhoidal disease and a normal digital rectal exam. Colonoscopy
was performed and demonstrated a 4-cm long circumferential and
ulcerated rectal mass, 12 cm from the anal verge. These ﬁndings
were conﬁrmed with rigid proctoscopy; and endoscopic biopsies
conﬁrmed adenocarcinoma and high-grade dysplasia arising in a
tubulovillous adenoma. Pelvic magnetic resonance imaging (MRI)
showed a tumor conﬁned to the rectal wall with no evidence of
adenopathy or a threatened circumferential resection margin. Fur-
ther oncologicwork-up, including a positron emission tomography
– computed tomography (PET-CT) did not show evidence of locally
invasive or metastatic disease.After preoperative clearance, the patient underwent a hand-
assisted laparoscopic anterior resection of the rectum without
complications. The patients’ postoperative course was uncompli-
cated and she was discharged on postoperative day seven. Final
s Ltd. This is an open access article under the CC BY-NC-ND license
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The differentiation of anal canal adenocarcinoma from other
adenocarcinomas is difﬁcult and diagnostic criteria have not been
well established. The utility of immunohistochemistry has beenig. 1. Intraoperative photograph showing a nodular lesion at the left lateral posi-
ion of the upper anal canal.
athology reported a 6/4.5/1.7 cm moderately differentiated ade-
ocarcinoma arising in a tubulovillous adenoma with positive
ymphovascular andperineural invasion, aswell as intraandperitu-
oral lymphocytic inﬁltrate. Twelve of 29 perirectal lymph nodes
howed evidence of metastatic disease (TNM classiﬁcation T3N2b,
tage IIIC). Mesorectal grading for completeness of resection was
good” and all resection margins were negative for malignancy.
iven the patients’ pathologic staging and the recommendations
y medical oncology, she received adjuvant chemotherapy (leu-
ovorin, ﬂuorouracil, and oxaliplatin [FOLFOX]), and long-course
adiotherapy (total of 45Gy fractioned over ﬁve weeks). She tol-
rated her adjuvant therapy well with no severe complications or
eed for hospital admission.
During post-treatment follow-up, the patient remained asymp-
omatic. Eleven months after surgery she underwent a follow-up
olonoscopy that showed a normal appearing and patent colorec-
al anastomosis at 15 cm from the anal verge. The rest of the
olonoscopy was normal. Digital rectal exam showed a mobile,
ale-yellow, 1-cm nodular lesion at the left lateral position of the
pper anal canal with a smooth surface (Fig. 1). There was no
vidence tumor ﬁxation, tethering, or ulceration. There was no
vidence of inguinal adenopathy. Biopsy of the anal canal lesion
howed poorly differentiated adenocarcinoma. Endoanal ultra-
ound demonstrated a 1 by 0.6 cmnodule at the left lateral position
f the upper anal canal without evidence of sphincter involvement
r adenopathy (Fig. 2). Pelvic MRI and PET-CT did not show evi-
ence of locally invasive or metastatic disease. Shortly thereafter,
he patient underwent a transanal excision of the lesion with 1-
m margins of normal-appearing tissue (Figs. 3 and 4). Additional
argins were excised and evaluated intraoperatively and showed
o evidence of malignancy. The patient tolerated the procedure
ell and there were no complications. Final pathology showed
high-grade poorly differentiated adenocarcinoma with positive
ymphovascular and perineural invasion (TNM classiﬁcation T1N0,
tage I). No lymphocytic inﬁltrate was noted and all margins were
egative for malignancy. Tissue staining showed positivity for
ytokeratin (CK) 20 and CDX2, and negative CK 7. Additional adju-
ant chemotherapy was recommended and the patient tolerated
his well. Six months after surgery, the patient is asymptomatic
ith no evidence of recurrent or metastatic disease.
. DiscussionCarcinomas of the anal canal are rare malignancies compris-
ng approximately 1–2%of all gastrointestinal carcinomas.1 Most
nal canal carcinomas are squamous cell carcinomas,with less thanFig. 2. Endoanal ultrasound demonstrating the location and position of a
metachronous adenocarcinoma of the anal canal.
20% being adenocarcinomas.2 There are two subtypes of anal canal
adenocarcinomas: (1) Colorectal (mucosal-based), and (2) Extra-
mucosal (ﬁstula-associated or anal gland). The colorectal subtype
originates in themucosa of the anal canal and is histologically iden-
tical to colorectal adenocarcinomas. The extramucosal subtype has
no overlying mucosal lesion and arises from the columnar epithe-
lium lining of anal glands. These glands open into the transitional
zone of the anal canal through the internal anal sphincter.3,4 This
subtype is more aggressive and has been frequently reported in
association with chronic anorectal ﬁstulas and Crohn’s disease.5,6
Adenocarcinomas extending down from the rectum are considered
rectal adenocarcinomas. Risk factors for the development of anal
canal adenocarcinoma include cigarette smoking, human immu-
nodeﬁciency virus infection, human papilloma virus infection and
anal intercourse.1,7–9Fig. 3. Intraoperative photograph after wide local excision of a metachronous ade-
nocarcinoma of the anal canal.
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Cig. 4. Gross pathologic specimen after transanal excision of a metachronous ade-
ocarcinoma of the anal canal.
eported in primary anal adenocarcinoma and speciﬁc markers
nclude p63, CK 5/6, CDX2, CK 7, CK 20.8 Speciﬁc immunohis-
ochemical patterns have been useful to distinguish anal canal
denocarcinoma subtypes (Table 1), and may play a role when
hoosing a treatment strategy.
The management of adenocarcinoma of the anal canal remains
ontroversial. High rates of pelvic failure and distant metastasis
mong patients with anal adenocarcinoma treated with surgery
lone or chemoradiotherapy have been reported.10,11 A retrospec-
ive review from the Rare Cancer Network in Europe reviewed
he outcomes of 82 patients with anal adenocarcinoma treated
ith multiple different modalities.10 Disease-free and overall sur-
ival were improved with chemoradiotherapy versus radiotherapy
lus surgery or surgery alone (risk ratio, 0.31 and 0.28; P<0.001).
ultivariate analysis showed that T and N stage, histologic grade,
nd treatment modality were signiﬁcant prognostic factors. The
uthors therefore recommended that deﬁnitive chemoradiother-
py should be considered for these patients and radical resection
hould be reserved for salvage. From a 20-year experience at the
D Anderson Cancer Center, Chang et al.11 reviewed the out-
omes of 28 patients with anal canal adenocarcinoma treated
ith local excision (n=13), and radical excision (n=15). Thirteen
atients received neoadjuvant chemoradiotherapy, 10 adjuvant
hemoradiotherapy, and 3 adjuvant radiotherapy alone. At a
edian follow-up of 37 months, median disease-free survival
as 13 months after local excision and 32 months after radi-
al surgery (P=0.055). Overall survival at 5 years was 43% for
able 1
mmunohistology patterns used to differentiate subtypes of primary anal canal
denocarcinoma.
Colorectal type Extramucosal type
p63 Negative Negative
CK 5/6 Negative Negative
CDX2 Positive Negative
CK 7 Occasionally positive Positive
CK 20 Positive Negative
K: cytokeratin.PEN ACCESS
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patients treated with local excision and 63% for patients treated
with radical surgery (P=0.3). Tumor grade was predictive of over-
all survival and recurrence. Based on this experience, the authors
recommended neoadjuvant chemoradiotherapy and radical exci-
sion. At Memorial Sloan-Kettering Cancer Center, 13 patients with
primary anal adenocarcinoma were followed for a median of 19
months after treatmentwith neoadjuvant chemoradiotherapy plus
abdominoperineal resection (n=5), local excision plus adjuvant
radiotherapy or chemoradiotherapy (n=5), or abdominoperineal
resection plus adjuvant chemoradiotherapy (n=3).12 Median sur-
vival was 26 months and local recurrence occurred in 37% of
patients. Patients treatedwithabdominoperineal resectionpluspre
or postoperative radiation or combinedmodality therapy had a 37%
local recurrence rate, and three of eight showed no evidence of dis-
ease at last follow-up. Patients who underwent local excision plus
adjuvant radiation or combined modality therapy had a 40% local
recurrence rate with one local failure salvaged by abdominoper-
ineal resection, and one of the ﬁve patients had no evidence of
disease upon follow-up.
The therapeutic approach andoncologic results of studies evalu-
ating the management of primary anal adenocarcinoma invariably
reﬂect surgeon and patient preference, as well as tumor stage.
Furthermore, the limited experience with a single therapeutic
approach is likely related to the rarity of this malignancy. Our case
report of primary anal canal adenocarcinoma is unique because it
was diagnosed 11 months after treatment of a primary rectal ade-
nocarcinoma.Adjuvant chemoradiotherapyhadalreadybeengiven
after her prior anterior resection; therefore, additional neoadju-
vant therapy was contraindicated. Local excision was performed
largely because of patient preference but immunohistology was
taken into account as well. Immunohistology was indicative of a
colorectal subtype anal adenocarcinoma, which has been reported
as less aggressive compared to the extramucosal subtype. Although
speciﬁc immunohistochemistry patterns may play a role in the
treatment of anal adenocarcinoma, treatment outcomes based on
immunohistology have not been reported. The decision to give
further adjuvant chemotherapy was based on the poor histologic
ﬁndings seen on ﬁnal pathology. The patient understands the
inherent risk of local and distant recurrence of disease and the
questionable role of salvage therapy. Currently, she is commit-
ted to a rigorous follow-up and screening program which involves
endoanal ultrasound, colonoscopy, and PET-CT.
4. Conclusion
In this rare case report, we present a metachronous anal canal
adenocarcinomadiagnosed11months after treatmentof a sporadic
primary rectal adenocarcinoma. Immunohistology was essential
to establish the diagnosis of a colorectal subtype anal adenocarci-
noma. Based on clinical and histologic characteristics of the tumor,
and imaging studies; transanal excision was performed.
Reports of anal canal adenocarcinoma in the current litera-
ture consist of small case series and retrospective reviews with
no clear consensus regarding the ideal treatment option. Despite
high local and distant failure rates with most available treatment
options, neoadjuvant chemoradiotherapy and radical resection are
recommended. Theuse of immunohistology to establish the correct
subtype of anal adenocarcinoma is essential, and in the future, cer-
tain immunohistologic patternsmay inﬂuence treatment strategies
of this rare cancer.Funding
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